Get the Stockscreener App
1.17
2.49%
-0.035
Aldeyra Therapeutics Inc stock is traded at $1.17, with a volume of 301.74K.
It is down -2.49% in the last 24 hours and down -20.88% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.205
Open:
$1.18
24h Volume:
301.74K
Relative Volume:
0.27
Market Cap:
$70.88M
Revenue:
-
Net Income/Loss:
$-27.37M
P/E Ratio:
-2.5703
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
-12.96%
1M Performance:
-20.88%
6M Performance:
-33.62%
1Y Performance:
-76.82%
1-Day Range:
$1.17
$1.22
1-Week Range:
$1.17
$1.40
52-Week Range:
$1.07
$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.175 | 72.69M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
527.65 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
764.67 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.06 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.50 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.50 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast - TradingKey
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX: Aldeyra Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Aldeyra Therapeutics, Inc. (ALDX) Latest Stock News & Headlines - Yahoo Finance
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-09-06 | Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALDX | Press Release - stockhouse.com
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo Finance
Here's Why You Should Add ARQT Stock to Your Portfolio Now - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - vinanet.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
ALDX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.09 per Share Points to Cost DisciplineMid-Term Outlook - careplusvn.com
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - accessnewswire.com
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.06 per Share Amid Pipeline-Focused StrategyRevenue Warning Signal - dars.gov.et
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results - marketbeat.com
Aldeyra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary - TradingView
Aldeyra Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Aldeyra Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
INVESTOR DEADLINE APPROACHING: Aldeyra Therapeutics (ALDX) Invest - The National Law Review
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics (ALDX) Drops 3.75% Toward Key $1.46 SupportMutual Fund Flow - careplusvn.com
Aldeyra Therapeutics (ALDX) Dips 3.75% to $1.54 — Approaching Critical Support ZoneVolatility Breakout Picks - dars.gov.et
Aldeyra Therapeutics, Inc. Signs Lease for New Corporate Headquarters in Concord, Massachusetts - marketscreener.com
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G - Stock Titan
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence - TradingKey
Aldeyra Therapeutics Inc (ALDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ALDX|Aldeyra Therapeutics Inc|Price:1.560|Chg%:+0.010 - TradingKey
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):